| Title | Chemotherapy of osteosarcoma: beyond conventional approaches to future concepts | ||
| Authors | Ch. Dokos, Κ. Kalousis, A. Kouyoumtzis and M. Mironidou-Tzouveleki
A’ Laboratory of Pharmacology, Medical School, Aristotle University, Thessaloniki, Greece |
||
| Citation | Dokos, C., Kalousis, K., Kouyoumtzis, A. and Minoridou-Tzouveleki, M.: Chemotherapy of osteosarcoma: beyond conventional approaches to future concepts, Epitheorese Klin. Farmakol. Farmakokinet. 22(2): 133-137 (2008) | ||
| Publication Date | 23-25 May 2008 | ||
| Full Text Language | English | ||
| Order – Buy | Ηλεκτρονική Μορφή: pdf (10 €) – Digital Type: pdf (10 €)
pharmakonpress[at]pharmakonpress[.]gr |
||
| Keywords | Osteosarcoma, chemotherapy, therapeutics, methotrexate, ifosfamide, cisplatin, doxorubicin, bisphosphonates, prognosis, COX-2 inhibitors. | ||
| Other Terms | Review article | ||
| Summary | Osteosarcoma or osteogenic sarcoma is a frequent primary malignant bone tumor with complex unbalanced karyotypes. It is primarily located in the metaphyseal region of distal femur and presents both numerical and structural cytogenetic abnormalities. It appears mostly in children and adolescents (men) and metastases emerge in more than 30% of the cases from the reactive zone of tumor (nodules called satellites) locally (as skip lesion) or systematically (lungs, other bones). Neoadjuvant multiagent chemotherapy seems to be the first line solution. Methotrexate, ifosfamide, cisplatin and doxorubicin are the main four cytostatic drugs used in chemotherapy protocols for osteosarcoma so as to increase the percentage of healing and further reduce mutilating surgery and toxicity. Even though survival rate has increased to 60% the problem of non-response to chemotherapy protocols still remains. Unfortunately it is estimated that 20% of the patients die from tumor metastasis. Beyond conventional chemotherapy protocols, studies indicate the need for prognostic factors in the chemotherapy response. Additionally new agents are under research for their therapeutic value in both neoadjuvant chemotherapy and chemotherapy resistance. Liposomal doxorubicin, bisphosphonates (zoledronic acid), VEGF inhibiting monoclonal antibodies, COX-2 inhibitors (meloxicam) are few of the future antineoplastic agents for established osteosarcoma therapy. | ||
| References | 1. Skinner B.H.: Current Diagnosis and Treatment in Orthopedics. Chapter 6: Μusculoskeletal Oncology. McGraw-Hill, 2006
2. Cotran S.R., Kumar V., Collins T. Robbins. Τhe Pathologic Basis of Diseases. WB Saunders Company, Chile, p. 1236-1237, 1999 3. Longhi A., Setola E., Versari M., Bacci G.: The role of chemotherapy in the treatment of bone and soft tissue sarcomas. Curr. Orthopaedics 18: 119-126 (2005) 4. Hartmann T.J., Kopp G.H.: Bone sarcomas. Update Cancer Therapeutics 1: 65-74 (2006) 5. Wittig C.J., Bickels J., Priebat D., Jelinek J., Graney-Kellar K., Shmookler B., Malawer M.M.: Osteosarcoma: a multidisciplinary approach to diagnosis and treatment. Am. Fam. Physician 65: 1123-1132 (2002) 6. Jansen-Cleton A.M., Buerger H., Hogendoorn W.C.P.: Central high-grade osteosarcoma of bone: diagnotic and genetic considerations. Curr. Diagn. Pathol. 11: 390-399 (2005) 7. Papachristou J.D., Papavassiliou G.A.: Osteosarcoma and chondrosarcoma: new signaling pathways as targets for novel therapeutic interventions. IJBCB 39: 857-862 (2007) 8. Gorlick R.: Osteosarcoma: clinical practice and the expanding role of biology. J. Musculoskel. Neuron. Interact. 2: 549-551 (2002) 9. Hansen M.F.: Genetic and molecular aspects of osteosarcoma. J. Musculoskel. Neuron. Interact. 2: 554-560 (2002) 10. Trieb K., Kotz R.: Proteins expressed in osteosarcoma and serum levels as prognostic factors. IJBCB 33:11-17 (2001). 11. Dokos C., Mironidou-Tzouveleki M.: Therapeutic strategies in management of Systematic Lupus Erythematosus (SLE): from classical therapeutic schemes to modern biological drugs. Orthopaedics 20: 23-32 (2007) 12. Brunton L., Lazo J., Parker K.: Goodman and Gillman’s: the Pharmacological Basis Of Therapeutics. Chapter 52: Αntineoplastic agents. McGraw-Hill, 2005 13. Dokos C., Mironidou-Tzouveleki M.: New trends and prospects of nanotechnology application in drug delivery. Epitheor. Klin. Farmakolol. Farmakokinet. 24: 165-172 (2006) 14. Bacci G., Bricolli A., Ferrari S., Longhi A., Mercuri M., Capanna R., Donati D., Lari S., Forni C., DePaolis M.: Neoadjuvant chemotherapy for osteosarcoma of the extremity: long term results of the Rizzoli’s 4th protocol. Eur. J. Cancer 37: 2030-2039 (2001) 15. Ferrari S., Smeland S., Mercuri M., Bertoni F., Longhi A., Ruggieri P., et al.: Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J. Clin. Onc. 23: 8845-8852 (2005) 16. Rao N.B., Galindo-Rodriguez C.: Intra-arterial cisplatin in osteosarcoma: same question, different answer. Ann. Surg. Oncol. 10: 481-483 (2003) 17. Daw C.N., Bilups A.C., Galindo-Rodriguez C., McCarville B.M., Rao N.B., Cain M.A., Jenkins J.J., Neel D.M., Meyer H.M.: Metastatic osteosarcoma: results of two consecutive trials at St. Jude Children’s Research Hopsital. Cancer 106: 403-412 (2006) 18. Fayette J., Blay Y.J.: Genetic predictors for drug resistance in soft tissue sarcoma: a review of publications in 2004. Curr. Opin. Oncol. 17: 370-375 (2005) 19. Kusuzaki K., Hirata M., Hideyuki T., Murata H., Hashiguchi S., Ashihara T., Hirasawa Y.: Relationship between P-glycoprotein positivity, doxorubicin binding ability and histologic response to chemotherapy in osteosarcomas. Cancer Letters 138: 203-208 (1999) 20. Kasper B., Ho D.A., Egerer G.: Is there an indication for high-dose chemotherapy in the treatment of bone and soft-tissue sarcoma? Oncology 68: 115-121 (2005) 21. Naruse T., Nishida Y., Hosomo K., Ishiguro N.: Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routes. Carcinogenesis 27: 584-592 (2006) 22. Fleisch H.: Development of bisphoshponates. Breast Cancer Res. 4: 30-34 (2002) 23. Heymann D., Ory B., Blanchard F., Heymann M.-F., Coipeau P., Charrier C., Couillaud S., Thiery J.P., Gouin F., Redini F.: Enhanced tumor regression and tissue repair when zoledronic acid is combined with isofosfamide in rat osteosarcoma. Bone 37: 74-86 (2005) 24. Horie N., Murata H., Nishigaki Y., Matsui T., Segawa H., Nogawa M., Yuasa T., Kimura S., Maekawa T., Fushiki S., Kubo T.: The third-generation bisphosphonates inhibit proliferation of murine osteosarcoma cells with induction of apoptosis. Cancer Letters 202: 509-515 (2006) 25. Kanakis I., Stathea X., Dedes P.G., Karamanos N.K.: Signaling pathways in cancer-induced bone disease and the inhibitory effect in bisphosphonates. Rev. Clin. Pharmacol. Pharmacokinet. 20: 18-191 (2006) |
||
| Relative Papers | |||
Online ISSN 1011-6575
Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:
- Chemical Abstracts
- Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Articles published in this Journal are Indexed or Abstracted in: • Chemical Abstracts • Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Συντακτικη Επιτροπή-Editorial Board
| ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ 2008 – ANNUAL SUBSCRIPTION 2008 | |
| Γλώσσα Πλήρους Κειμένου – Full Text Language | Αγγλικά – English |
| Παραγγελία – Αγορά – Order – Buy | Ηλεκτρονική Μορφή: pdf (70 €) – Digital Type: pdf (70 €)
pharmakonpress[at]pharmakonpress[.]gr |
| Έντυπη Μορφή (70 € + έξοδα αποστολής) – Printed Type (70 € + shipping)
pharmakonpress[at]pharmakonpress[.]gr |
|